Nivolumab provides improved effectiveness and safety compared with docetaxel as a second‐line treatment for advanced non‐small cell lung cancer: A systematic review and meta‐analysis

As an inhibitor of programmed death‐1 (PD‐1) protein, nivolumab has been shown to be effective in various cancers. We thus conducted this meta‐analysis to compare the relative efficacy of nivolumab vs docetaxel‐based chemotherapy as a second‐line treatment for previously treated advanced non‐small cell lung cancer (NSCLC)